HPV16-Expressing Tumors Release Multiple IL-1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine

Morgane Lecointre; Jérémy Guillot; Rachel Marcone; Dilara Ozdoganlar; Marjorie Cayatte; Elin Jaensson Gyllenbäck; David Liberg; Nadine Fournier; Krisztian Homicsko; Douglas Hanahan

doi:10.1158/2159-8290.CD-25-0382

HPV16-Expressing Tumors Release Multiple IL-1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine

Cancer Discov. 2025 Apr 27:OF1-OF26. doi: 10.1158/2159-8290.CD-25-0382. Online ahead of print.

Authors

Morgane Lecointre^#^{1

2

3}, Jérémy Guillot^#^{1

2

3}, Rachel Marcone^{3

4}, Dilara Ozdoganlar^{1

2

3}, Marjorie Cayatte^{1

2

3}, Elin Jaensson Gyllenbäck⁵, David Liberg⁵, Nadine Fournier^{3

4}, Krisztian Homicsko^{1

2

3

6

7}, Douglas Hanahan^{1

2

3

8}

Affiliations

¹ Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland.
² Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
³ Agora Translational Cancer Research Center, Lausanne, Switzerland.
⁴ Bioinformatics Core Facility, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
⁵ Cantargia AB, Lund, Sweden.
⁶ Department of Oncology, CHUV, Lausanne, Switzerland.
⁷ Center for Personalized Oncology, CHUV, Lausanne, Switzerland.
⁸ Ludwig Institute for Cancer Research, Lausanne, Switzerland.

^# Contributed equally.

PMID: 40287949
DOI: 10.1158/2159-8290.CD-25-0382

Abstract

Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, inferentially due to systemic immunosuppression. This study elucidated an actionable mechanism, whose disruption renders an oncoprotein vaccine efficacious, with translational potential.

Abstract

Grants and funding